Mind Medicine (MindMed) is a clinical-stage biopharmaceutical company based in New York, focused on developing novel treatments for brain health disorders, including MM-120 for anxiety and ADHD, and MM-402 for autism. Founded in 2015, the company employs 57 people and targets neurotransmitter pathways using psychedelics and empathogens.
MNMD has been in the news recently: KaliVir Immunotherapeutics has appointed Schond Greenway as Chief Financial Officer (CFO) to enhance its financial operations. Greenway brings 25 years of experience in biotech finance to support the company's cancer treatment programs.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
